NEWS
AIM-HI
The AIM-HI Accelerator Fund Recognizes, Honors, and Congratulates Its 2023 Women’s Venture Competition Top Winners
Degron Therapeutics and its Co-founder and CEO, Lily Zou, Ph.D., MBA wins the Second Prize
C&EN
Molecular glues are beginning to stick
Degron Therapeutics is featured in the article about molecular-glue drug discovery
BIOCENTURY
June 9 Quick Takes: Venture rounds for Tessa, Degron, Ancora, Charm and Relation
Cross-border molecular glue newcoDegron raises $22M series A
BioWorld
Degron raises $22M to develop molecular glue-based protein degradation platform
Degron Therapeutics Inc. has raised $22 million in a series A round to develop its drug development
